ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3

Biochemical and Biophysical Research Communications

Volumn 315, Issue 1, 2004, Pages 79-84

  Mochizuki, Satsuki ^a   Shimoda, Masayuki ^a   Shiomi, Takayuki ^a   Fujii, Yutaka ^b   Okada, Yasunori ^a  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

ADAM28; Insulin like growth factor; Insulin like growth factor binding protein 3; MMP 7; TIMP 3

Indexed keywords

1,10 PHENANTHROLINE; EDETIC ACID; ENZYME PRECURSOR; MATRILYSIN; METALLOPROTEINASE; METALLOPROTEINASE ADAM28; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING;

EID: 0842308119     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.01.022     Document Type: Article

References (31)

1. Seals D.F., Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17:2003;7-30.
2. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Strinivasan S.et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 385:1997;729-733.
3. Allport J.R., Ding H.T., Ager A., Steeber D.A., Tedder T.F., Luscinskas F.W. L-selectin shedding does not regulate human neutrophil attachment, rolling, or transmigration across human vascular endothelium in vitro. J. Immunol. 158:1997;4365-4372.
4. Asakura M., Kitakaze M., Takashima S., Liao Y., Ishikura F., Yoshinaka T., Ohmote H., Node K., Yoshino K., Ishiguro H.et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 8:2002;35-40.
5. Nath D., Slocombe P.M., Webster A., Stephens P.E., Docherty A.J., Murphy G. Meltrin gamma (ADAM-9) mediates cellular adhesion through alpha(6)beta(1) integrin, leading to a marked induction of fibroblast cell motility. J. Cell Sci. 113:2000;2319-2328.
6. Roberts C.M., Tani P.H., Bridges L.C., Laszik Z., Bowditch R.D. MDC-L, a novel metalloprotease disintegrin cysteine-reich protein family member expressed by human lymphocytes. J. Biol. Chem. 274:1999;29251-29259.
7. Howard L., Maciewicz R.A., Blobel C.P. Cloning and characterization of ADAM28: evidence for autocatalytic pro-domain removal and for cell surface localization of mature ADAM28. Biochem. J. 348:2000;21-27.
8. Howard L., Zheng Y., Horrocks M., Maciewicz R.A., Blobel C. Catalytic activity of ADAM28. FEBS Lett. 498:2001;82-86.
9. Fourie A.M., Coles F., Moreno V., Karlsson L. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J. Biol. Chem. 278:2003;30469-30477.
10. Bridges L.C., Tani P.H., Hanson K.R., Roberts C.M., Judkins M.B., Bowditch R.D. The lymphocyte metalloprotease MDC-L (ADAM28) is a ligand for the integrin alpha4beta1. J. Biol. Chem. 277:2002;3784-3792.
11. Bridges L.C., Hanson K.R., Tani P.H., Mather T., Bowditch R.D. Integrin alpha4beta1-dependent adhesion to ADAM28 (MDC-L) requires an extended surface of the disintegrin domain. Biochemistry. 42:2003;3734-3741.
12. Dufourny B., Alblas J., van Teeffelen H.A., van Schaik F.M., van der Burg B., Steenbergh P.H., Sussenbach J.S. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J. Biol. Chem. 272:1997;31163-31171.
13. Firth S.M., Baxter R.C. Cellular actions of the insulin-like growth factor binding protein. Endocr. Rev. 23:2002;824-854.
14. Hwa V., Oh Y., Rosenfeld R.G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev. 20:1999;761-787.
15. Baxter R.C. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am. J. Physiol. Endocrinol. Metab. 278:2000;E967-E976.
16. Hamelers I.H., Steenbergh P.H. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr. Relat. Cancer. 10:2003;331-345.
17. Baxter R.C. Circulating-binding proteins for the insulin like growth factors. Trends Endocrinol. Metab. 4:1993;91-96.
18. Loechel F., Fox J.W., Murphy G., Albrechtsen R., Wewer U.M. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem. Biophys. Res. Commun. 278:2000;511-515.
19. Pacheco M.M., Mourao M., Mantovani E.B., Nishimoto I.N., Brentani M.M. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin. Exp. Metastasis. 16:1998;577-585.
20. Imai K., Yokohama Y., Nakanish I., Ohuchi E., Fuji Y., Nakai N., Okada Y. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J. Biol. Chem. 270:1995;6691-6697.
21. Inoki I., Shiomi T., Hashimoto G., Enomoto H., Nakamura H., Makino K., Ikeda E., Takata S., Kobayashi K., Okada Y. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 16:2002;219-221.
22. Loechel F., Gilpin B.J., Engvall E., Albrechtsen R., Wewer U.M. Human ADAM12 (meltrin alpha) is an active metalloprotease. J. Biol. Chem. 273:1998;16993-16997.
23. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases, structure, functions, and biochemistry. Circ. Res. 92:2003;827-829.
24. Wood W.I., Cachianes G., Henzel W.J., Winslow G.A., Spencer S.A., Hellmiss R., Martin J.L., Baxter R.C. Cloning and expression of the growth hormone-dependent insulin-like growth factor-binding protein. Mol. Endocrinol. 2:1988;1176-1185.
25. Amour A., Knight C.G., Webster A., Slocombe P.M., Stephens P.E., Knauper V., Docherty A.J., Murphy G. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 473:2000;275-279.
26. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., Stephens P.E., Shelley C., Hutton M., Knauper V., Docherty A.J., Murphy G. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435:1998;39-44.
27. Kashiwagi M., Tortorella M., Nagase H., Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem. 276:2001;12501-12504.
28. Roghani M., Becherer J.D., Moss M.L., Atherton R.E., Erdjument-Bromage H., Arribas J., Blackburn R.K., Weskamp G., Tempst P., Blobel C.P. Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J. Biol. Chem. 274:1999;3531-3540.
29. Clarke H.R., Wolfson M.F., Rauch C.T., Castner B.J., Huang C.P., Gerhart M.J., Johnson R.S., Cerretti D.P., Paxton R.J., Price V.L., Black R.A. Expression and purification of correctly processed, active human TACE catalytic domain in Saccharomyces cerevisiase. Protein Expr. Purif. 13:1998;104-110.
30. Fowlkes J.L., Enghild J.J., Suzuki K., Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem. 269:1994;25742-25746.
31. Salahifar H., Firth S.M., Baxter R.C., Martin J.L. Characterization of an amino-terminal fragment of insulin-like growth factor binding protein-3 and its effects in MCF-7 breast cancer cells. Growth Horm. IGF Res. 10:2000;367-377.